Navigation Links
Regeneron and Bayer Announce Co-Promotion Agreement With Santen For EYLEA® (aflibercept) Injection in Japan
Date:5/7/2012

TARRYTOWN, N.Y., May 8, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) and Bayer HealthCare today announced that Bayer's Japanese subsidiary, Bayer Yakuhin, Ltd. ("Bayer Yakuhin"), and Santen Pharmaceutical Co., Ltd.（"Santen"）entered into a co-promotion agreement for EYLEA® (aflibercept) Injection in Japan.  As previously announced, Bayer Yakuhin has submitted an application for marketing authorization to the Ministry of Health, Labor and Welfare (MHLW) for EYLEA for the treatment of neovascular age-related macular degeneration (wet AMD).

"With this agreement and upon marketing authorization, a newly formed Bayer Yakuhin ophthalmology field force and Santen, the leading ophthalmology company in Japan, will promote EYLEA," said Sebastian Guth, President & CEO of Bayer Yakuhin, Ltd.  "We expect that the combined resources of the two companies will allow EYLEA to achieve a broader and faster reach into the Japanese ophthalmology community and potentially benefit a greater number of patients."

Bayer and Regeneron have also amended their existing global license and collaboration agreement for EYLEA to convert the 50/50 profit share for Japan into a royalty arrangement that approximates the economics of the profit split.  In certain specified circumstances, the royalty may revert to a profit share arrangement.

EYLEA is approved for sale in the United States for the treatment of wet AMD and marketing approval has also been granted in Australia.  Bayer HealthCare has submitted applications in Europe and other countries and has initiated a Phase 3 clinical study for wet AMD in China. Beyond the wet AMD indication, EYLEA is in Phase 3 clinical studies for the treatment of diabetic macular edema (DME), myopic choroidal neovascularization (mCNV), and branch retinal vein occlusion (BRVO).  Regeneron
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Regeneron to Report First Quarter 2012 Financial and Operating Results and Host Conference Call and Webcast on April 26, 2012
2. Regeneron Announces Data Publication and Presentations with Potential First-in-Class Lipid-Lowering PCSK9 Antibody
3. Regeneron Announces February 2012 Investor Conference Presentations
4. Regeneron to Report Full Year 2011 Financial and Operating Results and Host Conference Call and Webcast on February 16, 2012
5. Regeneron Announces Settlement of Patent Litigation with Genentech for U.S. Ophthalmic Sales of EYLEA™ (aflibercept) Injection
6. Regeneron to Host Conference Call on January 3 at 8:30 a.m. Eastern Time to Discuss Ongoing Patent Litigation
7. Regeneron Announces Presentation Time Change at the 2011 Deutsche Bank BioFEST
8. Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review
9. Rockefeller University President Marc Tessier-Lavigne Elected to Regeneron Board of Directors
10. Regeneron Announces FDA Approval of EYLEA™ (aflibercept) Injection for the Treatment of Wet Age-Related Macular Degeneration
11. Sanofi and Regeneron Report Positive Preliminary Phase 2 Program Results for Anti-PCSK9 Antibody in Hypercholesterolemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... 20, 2013 Sequent Medical, Inc. announced today ... ("Single Layer") family of WEB ® Aneurysm Embolization ... new models in select neurovascular centers in Europe.  The ... that will enable physicians to treat a broader range ... SL configurations are made possible by further advancement of ...
(Date:5/20/2013)... NEW YORK , LONDON , ... , May 20, 2013 ... Prevalence of Osteoarthritis and Preference for Minimally Invasive Procedures ... competitive landscape, and market trends for the six arthroscopy ... Systems (FMSs), arthroscopy implants, arthroscopy radio frequency systems, and ...
(Date:5/20/2013)... , May 20, 2013  Medicare Part ... are overwhelmingly satisfied, citing lower costs, convenient access ... new survey from Hart Research Associates released today ... than 40% of Part D seniors (9.5 million) ... "Seniors like the lower costs, pharmacy ...
Breaking Medicine Technology:Sequent Medical, Inc. Launches New SL Family of WEB Aneurysm Embolization Devices 2Increasing Prevalence of Osteoarthritis and Preference for Minimally Invasive Procedures to Drive Arthroscopy Devices Market Growth 2Increasing Prevalence of Osteoarthritis and Preference for Minimally Invasive Procedures to Drive Arthroscopy Devices Market Growth 3Increasing Prevalence of Osteoarthritis and Preference for Minimally Invasive Procedures to Drive Arthroscopy Devices Market Growth 4Survey: 85% of Part D Seniors in Preferred Pharmacy Plans are Satisfied With Costs, Pharmacy Choices 2
(Date:5/21/2013)... The National Resident Matching Program NRMP® ... its Board of Directors. Hal B. Jenson, M.D., ... of Medicine, has been named President. Maria C. ... of California San Diego, is the President-Designate, and Glenn ... Medical Center, is the Secretary-Treasurer. Kenneth B. Simons, ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 The Michigan ... meeting in Lapeer on , June 11th. , Meeting ... Location: Lapeer Regional Medical Center,     Conference Room 5 (Lower ... These meetings are designed to assist people with lupus ... one another, and to get a better understanding of ...
(Date:5/21/2013)... The birth control safety advocates at DrugRisk.com ... the contraceptive NuvaRing. A new report shows the number ... increased in recent months*. , DrugRisk was created to ... the latest safety alerts, recalls, studies and legal news. ... side effects and decide if they need legal advice. ...
(Date:5/20/2013)... (PRWEB) May 21, 2013 USA Book ... Transcendent Approach to Peak Performance" won the top honor ... Category. Chosen over a multitude of international titles ... attention and critical acclaim from both mainstream and new ... - mentally, physically and spiritually. , “The ...
(Date:5/20/2013)... Dallas, Texas (PRWEB) May 21, 2013 ... based on product type into two categories - ... AED market is classified into five categories, namely, ... the market is forecast till 2017. Automated external ... lives of sudden cardiac arrest victims. Considering the ...
Breaking Medicine News(10 mins):Health News:New Board of Directors Leadership for The Match- National Resident Matching Program® 2Health News:New Board of Directors Leadership for The Match- National Resident Matching Program® 3Health News:DrugRisk Update Shows Increase in NuvaRing Blood Clot Lawsuits 2Health News:Mystic Ink Publishing's "The Infinity Zone" Wins Top Honor - International Book Awards 2Health News:Mystic Ink Publishing's "The Infinity Zone" Wins Top Honor - International Book Awards 3Health News:North America Leads Automated External Defibrillator Market (AED), Says New Research Report at ReportsnReports.com 2Health News:North America Leads Automated External Defibrillator Market (AED), Says New Research Report at ReportsnReports.com 3
... 9, 2010, describes the discovery of an alternative form of ... sterilize them. Nematodes are among the most abundant, diverse and ... via Symbiosis; Recent Spread of a Drosophila Defensive ... and his colleagues. In a video interview, Jaenike explains the ...
... ... a range of preventable health problems, Sam’s Club is hosting free health screenings in more ... , ... July 8, 2010 -- To help its members and community residents detect a range of ...
... , THURSDAY, July 8 (HealthDay News) -- Scientists report they,ve ... "soldiers" in the immune system that might prevent the AIDS ... researchers, these newly found antibodies connect with and neutralize more ... all major genetic subtypes of the virus. That breadth ...
... provide authors additional time to complete their research, the ... 31 for the Cell Symposia meeting, Influenza: Translating basic ... Marriott Hotel in Washington, DC., Abstracts are invited for ... "Virus biology," "Pandemics, pathogenesis and disease," "Immune response and ...
... . Montreal, July 8, 2010 - A team of ... Cancer (IRIC) of the University of Montreal have identified ... IRIC Principal Investigators Martine Raymond, Alain Verreault and Pierre ... Research Institute of the National Research Council Canada, the ...
... NC Men who have a baseline PSA value of ... up to 11 times more likely to die from prostate ... to Duke University Medical Center researchers. Scientists say ... , supports routine, early prostate-specific antigen (PSA) screening among healthy ...
Cached Medicine News:Health News:Sam's Club Hosts Health Screenings July 10 2Health News:New Anti-HIV Weapons Found in Immune System 2Health News:Cell symposia meeting, Influenza: Translating basic insights, to be held Dec. 2-4, 2010 2Health News:Vitamin B3 as a novel approach to treat fungal infections 2Health News:Baseline PSA predicts risk of death from prostate cancer 2
... the injection of contrast medium, anesthetic gel, ... design eliminates the need for multiple catheterizations. ... atraumatic passage into and through the ureter. ... polymer that when activated, attracts and holds ...
Used for drainage and retrograde pyelogram. Supplied sterile in peel-open packages. Intended for one-time use....
Used for directing a flexible tipped wire guide in the ureter. The angled tip allows passage of the catheter past a ureteral stone in preparation for E.S.W.L. Supplied sterile in peel-open packages. ...
Used for drainage and navigation of a tortuous ureter. The tapered tip eases placement as there are no edges to interfere with the ureteral orifice. Supplied sterile in peel-open packages. Intended f...
Medicine Products: